Skip to Content

Nuwiq Approval History

FDA Approved: Yes (First approved September 4, 2015)
Brand name: Nuwiq
Generic name: antihemophilic factor (recombinant)
Dosage form: for Injection
Company: Octapharma USA, Inc.
Treatment for: Hemophilia A

Nuwiq (antihemophilic factor [recombinant]) is recombinant blood coagulation factor VIII indicated for the control and prevention of bleeding episodes in patients with hemophilia A.

Development History and FDA Approval Process for Nuwiq

DateArticle
Sep 15, 2015Approval FDA Approves Nuwiq (Antihemophilic Factor [Recombinant]) for Hemophilia A

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide